VIENNALAB

ViennaLab is proud of its engagement in product development, promoting original IVD StripAssay® and RealFastTM kits worldwide with its existing network of distribution partners, guaranteeing international presence.

ViennaLab Diagnostics offers a variety of easy-to-use in vitro diagnostic kits for the detection of genetic mutations, as well as genetic predispositions, pharmacogenetics and oncology.

ViennaLab StripAssays® and RealFast™ Assays are easy, reliable and affordable – better than any other assay currently on the market.

StripAssays®

Human diagnostic assays for genotyping mutations and polymorphisms (SNPs, deletions, insertions) based on polymerase chain reaction (PCR) and reverse-hybridzation to allele-specific oligonucleotide probes immobilized on teststrips

  • Simple and straightforward protocols
  • Manual or automated
  • Less than 6 hours from DNA to result
  • Easy and clear interpretation of results
  • Additional mutations readily integrated
  • Ready-to-use reagents; inexpensive equipment; CE/IVD labeled kits; sensitive and affordable

01  FMF STRIPASSAY®

Testing for Familial Mediterranean Fever and Risk Factors for Amyloidosis

02  CAH STRIPASSAY®

Congenital adrenal hyperplasia (CAH) is an inherited disorder of steroid hormone synthesis.

03  CF STRIPASSAY®

Identify the most relevant CFTR mutations and variants for newborn screening and confirmatory genotyping

04  LACTOSE INTOLERANCE STRIPASSAY®

Many people do not have the necessary enzymes in sufficient quantities to digest lactose and fructose.

05  SUGAR INTOLERANCE STRIPASSAY®

ViennaLab assays identify the most frequent genetic variations responsible for sugar intolerance.

06  PGX-THROMBO STRIPASSAY®

ViennaLab assays identify the most relevant genetic variations influencing coumarin anticoagulation therapy.

07  PGX-TPMT STRIPASSAY®

The PGX-TPMT StripAssay® identifies the most frequent polymorphisms in the TPMT gene with therapeutic relevance.

08  PGX-CYP2C19 STRIPASSAY®

The PGX-CYP2C19 StripAssay® detects genetic variants resulting in reduced or increased activity of the cytochrome P450 isoenzyme CYP2C19.

09  PGX-CYP2D6 STRIPASSAY®

The PGX-CYP2D6 StripAssay® detects the most common variants with impaired enzyme activity.

10  BRAF 600/601 STRIPASSAY®

The BRAF StripAssays® rapidly identify the most relevant mutations in the BRAF gene.

11  NRAS XL STRIPASSAY®

The KRAS and NRAS StripAssays® rapidly identify the most relevant mutations in the KRAS and NRAS genes.

12  KRAS XL STRIPASSAY®

The KRAS and NRAS StripAssays® rapidly identify the most relevant mutations in the KRAS and NRAS genes.

13  EGFR XL STRIPASSAY®

The EGFR StripAssay® identifies the most important mutations relevant for anti EGFR-TK therapy

14  HLA-B27 STRIPASSAY®

ViennaLab HLA-B27 assays detect all disease-relevant HLA-B27 subtypes.

15  CVD STRIPASSAY® T

CVD StripAssays® and RealFast™ Assays identify various combinations of genetic CVD risk factors.

16  CVD STRIPASSAY® A

Identify the most relevant genetic variations to estimate the risk for Cardiovascular Diseases

17  HAEMOCHROMATOSIS STRIPASSAY® B

ViennaLab assays identify the most common mutations causing iron overload.

RealFast™ Assays

RealFastTM Assays based on real-time PCR detect single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) fast and simply.

  • Fast and easy handling
  • Same protocol for all genotyping assays
  • Less than 90 min from DNA to result
  • Controls for wild type and mutant genotypes included
  • Compatible with many real-time PCR instruments

Ready-to-use reagents; inexpensive equipment; CE/IVD labeled kits; sensitive and affordable

01  FV LEIDEN REALFAST™ ASSAY

Detects the most common genetic risk factor associated with venous thromboembolism, the 1691G>A mutation in the Factor V (FV) gene

02  FV-PTH MPX REALFAST™ ASSAY

Simultaneous detection of the most important thrombophilic mutations 1691G>A in the Factor V gene and 20210G>A in the prothrombin gene

03  PTH 20210G>A REALFAST™ ASSAY

Detects the most common genetic risk factor associated with venous thromboembolism, the 1691G>A mutation in the Factor V (FV) gene

04  HFE C282Y REALFAST™ ASSAY

Detect common mutations in the HFE gene causing hereditary haemochromatosis (HH) type 1

05  HFE MPX REALFAST™ ASSAY

Simultaneous detection of the two most common mutations in the HFE gene: H63D and C282Y

06  LCT -13910C>T REALFAST™ ASSAY

Detects the most common polymorphism in the lactase (LCT) gene causing lactase non-persistence

07  MTHFR 677C>T REALFAST™ ASSAY

Detect common mutations in the methylenetetrahydrofolate reductase (MTHFR) gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease

08  MTHFR MPX REALFAST™ ASSAY

Simultaneous detection of the most common two mutations in the MTHFR gene: 677C>T and 1298A>C

09  MTHFR 1298A>C REALFAST™ ASSAY

Detect common mutations in the methylenetetrahydrofolate reductase (MTHFR) gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease

10  PAI-1 4G/5G REALFAST™ ASSAY

Detects the 4G risk allele in the plasminogen activator inhibitor-1 (PAI-1) gene, associated with cardiovascular disease and pregnancy complications

11  SLCO1B1C.521T>C REALFAST™ ASSAY

Detects a variant in human solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene in patients who are at higher risk for developing statin-induced myopathy

12  HLA-B5701 REALFAST™ ASSAY

Detects human leukocyte antigen-B (HLA-B) 5701 allele, which is associated with hypersensitivity to the anti-HIV drug abacavir

13  HLA-B27 REALFAST™ ASSAY

Detects the human leukocyte antigen-B (HLA-B) 27 allele, which is associated with ankylosing spondylitis

14  EGFR T790M REALFAST™ ASSAY

Detects the T790M mutation in the EGFR gene from cell-free DNA. For monitoring of lung cancer patients who undergo treatment with EGFR tyrosine kinase inhibitors.

Related projects

CytoTrack offers breakthrough technology for the detection of Circulating Tumor Cells (CTCs).

PHOENIXDX® SARS-COV-2 MULTIPLEX IVD is a real-time RT-PCR-based diagnostic test for the in vitro qualitative detection of 2019-Novel Coronavirus (SARS-CoV-2) in respiratory specimens and sera from patients who meet COVID-19 clinical and/or epidemiological criteria.

Atana biosensor systems are based on Quartz Crystal Microbalance (QCM) technology. Sensor surfaces allow systems to be used to study a variety of molecular interactions of different biomolecules, including proteins, nucleic acids, and cells.

Copyright © 2020 Bi-MEK. All rights reserved.

Copyright © 2020 Bi-MEK. All rights reserved.

Copyright © 2020 Bi-MEK. All rights reserved.